NTLA's logo.
Ticker Symbol: NTLA

Intellia Therapeutics Inc

$137.51 - 02-12-2024 4 p.m. ET

Exchange: NASDAQ Country: US Currency: USD Asset Type: Common Stock CIK:0001652130

Company Profile

Intellia Therapeutics is a leading clinical-stage genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creating enhanced engineered cells that can treat oncological and immunological diseases. Intellia's combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts it in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create new classes of therapeutic products.

Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Standard Industrial Classification Code (SIC code): 2835
Address: 40 Erie St Ste 130
CEO: John Leonard
Tags:
  • Health Technology
  • Biotechnology
  • Manufacturing
  • Pharmaceutical Preparation Manufacturing

Pricing

Last Updated: October 3, 2023 03:00 PM EST
Previous Close: $29.68
Change: $0.27 ( 0.92%)
Days Range: $28.78 - $29.96
Beta: 1.67
52wk. High: $57.49
52wk. Low: $26.65
Ytd. Change -14.79%
50 Day Moving Average: $32.72
200 Day Moving Average: $38.64
Shares Outstanding: 88490950

Valuation

Market Cap: 262.6B
PE Ratio: -5.46
EPS (TTM): -5.44

Dividends

Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A